Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label single-arm TPI 287 in previously gemcitabine-treated advanced unresectable pancreatic cancer
2007-005783-27Phase 2Active
- Sponsor
- Tapestry Pharmaceuticals, Inc.
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abeotaxane in pancreatic cancer (PC), sponsored by Tapestry Pharmaceuticals, Inc. Primary endpoint: 6-month survival rate. Started Feb 2008; status: active.
02
Drugs
abeotaxane
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2007-005783-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005783-27.